Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart

被引:21
作者
Dautzenberg, FM
Higelin, J
Brauns, O
Butscha, B
Hauger, RL
机构
[1] Axovan Ltd, Innovat Ctr, CH-4070 Allschwil, Switzerland
[2] F Hoffmann La Roche & Co Ltd, Div Pharma, Preclin Res, CH-4002 Basel, Switzerland
[3] Max Planck Inst Expt Med, Dept Neuroendocrinol, D-37075 Gottingen, Germany
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] Vet Affairs Med Ctr, Dept Psychiat, La Jolla, CA USA
关键词
D O I
10.1124/mol.61.5.1132
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ligand selectivity of human (hCRF(2A)) and Xenopus laevis (xCRF(2)) forms of the corticotropin-releasing factor type 2 (CRF2) receptor differs. The purpose of this study was to identify amino acids in these two CRF2 receptors conferring these differences. An amino acid triplet in the third extracellular domain (Asp(262)Leu(263)Val(264) in hCRF(2A) or Lys(264)Tyr(265)IIe(266) in xCRF(2)) was found to diverge between both receptors. When binding and signaling characteristics of receptor mutants hR2KYI and xR2DLV were assessed, the tri-amino acid motif replacement produced receptors with binding properties resembling the xCRF(2) receptor. The converse mutation created a mutant receptor with a binding pharmacology identical to the profile of the hCRF(2A) receptor. This effect was most notable for xR2DLV, which possessed a binding affinity for astressin similar to15-fold greater for astressin than sauvagine. In contrast, the binding profiles of the hCRF(2A) receptor and hR2KYI did not differ. These data indicate that another domain of the xCRF(2) receptor mediated low-affinity binding of astressin. Two amino acids in the first extracellular domain differ in xCRF(2) (Asp(69)Ser(70)) and hCRF(2A) (Glu(66)Tyr(67)) receptors. The hCRF(2A) receptor mutant (hR2DS-KYI) bound astressin with a low affinity indistinguishable from the xCRF(2) receptor. Therefore, these data demonstrate that ligand selectivity differences between amphibian and human forms of the CRF2A receptor are governed by these two motifs of the extracellular domains of the xCRF(2) receptor.
引用
收藏
页码:1132 / 1139
页数:8
相关论文
共 35 条
[1]   The role of corticotropin-releasing factor in depression and anxiety disorders [J].
Arborelius, L ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
JOURNAL OF ENDOCRINOLOGY, 1999, 160 (01) :1-12
[2]   Human CRF2 α and β splice variants:: pharmacological characterization using radioligand binding and a luciferase gene expression assay [J].
Ardati, A ;
Goetschy, V ;
Gottowick, J ;
Henriot, S ;
Valdenaire, O ;
Deuschle, U ;
Kilpatrick, GJ .
NEUROPHARMACOLOGY, 1999, 38 (03) :441-448
[3]   Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction [J].
Assil, IQ ;
Qi, LJ ;
Arai, M ;
Shomali, M ;
Abou-Samra, AB .
BIOCHEMISTRY, 2001, 40 (05) :1187-1195
[4]   Pharmacological and chemical properties of astressin, antisauvagine-30 and α-helCRF:: significance for behavioral experiments [J].
Brauns, O ;
Liepold, T ;
Radulovic, J ;
Spiess, J .
NEUROPHARMACOLOGY, 2001, 41 (04) :507-516
[5]  
Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640
[6]   Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1:: Implications for the ligand-binding site [J].
Dautzenberg, FM ;
Wille, S ;
Lohmann, R ;
Spiess, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :4941-4946
[7]   The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: Generation of chimeric receptors with a novel ligand-selective profile [J].
Dautzenberg, FM ;
Kilpatrick, GJ ;
Wille, S ;
Hauger, RL .
JOURNAL OF NEUROCHEMISTRY, 1999, 73 (02) :821-829
[8]   Evidence for the abundant expression of arginine 185 containing human CRF2α receptors and the role of position 185 for receptor-ligand selectivity [J].
Dautzenberg, FM ;
Huber, G ;
Higelin, J ;
Py-Lang, G ;
Kilpatrick, GJ .
NEUROPHARMACOLOGY, 2000, 39 (08) :1368-1376
[9]  
Dautzenberg FM, 2001, J PHARMACOL EXP THER, V298, P812
[10]  
Dautzenberg FM, 2001, J PHARMACOL EXP THER, V296, P113